CS
STOK icon

Credit Suisse’s Stoke Therapeutics STOK Stock Holding History

Credit Suisse’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,449
Closed -$49K – 3145
2023
Q3 		$49K Sell
12,449
-1,062
-8% -$6.98K ﹤0.01% 3116
2023
Q2 		$144K Buy
+13,511
New +$144K ﹤0.01% 3118
2023
Q1 		– Sell
-9,859
Closed -$91K – 3676
2022
Q4 		$91K Buy
9,859
+20
+0.2% +$208 ﹤0.01% 3348
2022
Q3 		$126K Buy
9,839
+109
+1% +$1.74K ﹤0.01% 3388
2022
Q2 		$129K Buy
+9,730
New +$148K ﹤0.01% 3471
2021
Q2 		– Sell
-6,151
Closed -$238K – 4602
2021
Q1 		$238K Sell
6,151
-7,014
-53% -$399K ﹤0.01% 4076
2020
Q4 		$815K Buy
13,165
+5,884
+81% +$270K ﹤0.01% 3479
2020
Q3 		$243K Buy
+7,281
New +$208K ﹤0.01% 3761

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse's STOK Position: Q4 2023 in Review

Credit Suisse sold out of Stoke Therapeutics (STOK) in Q4 2023, closing a stake of 12,449 shares — an estimated $49K sold.

Credit Suisse first reported a position in STOK in Q3 2020 and held it in 8 quarters. The position peaked at $815K in Q4 2020. 81 funds tracked by Wall St. Rank hold STOK as of Q4 2023.

  • Credit Suisse reported no remaining Stoke Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Credit Suisse sold 12,449 Stoke Therapeutics shares in Q4 2023, an estimated $49K.
  • Credit Suisse first reported a position in Stoke Therapeutics in Q3 2020 and held it in 8 quarters.
  • Credit Suisse's Stoke Therapeutics position peaked at $815K in Q4 2020.
  • 81 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2023.

Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.